Trends in Cancer
TrendsTalkChristopher Kemp and Carla Grandori: The Promise of Functional Precision Medicine
Section snippets
Main Text
Remarkable advances in genomic profiling of tumors have not translated easily into effective personalized therapies for many patients. Functional precision medicine brings forward an alternative approach, one where the drug-sensitivity phenotype of individual tumors is layered onto the genotype information. Christopher Kemp hailing from the Fred Hutchinson Cancer Research Center in Seattle, and Carla Grandori jointly founded Cure First and SEngine Precision Medicine, organizations that are
Resources
References (0)
Cited by (1)
Rational Cancer Treatment Combinations: An Urgent Clinical Need
2020, Molecular CellCitation Excerpt :In organoids derived from lung squamous cell carcinoma mouse models, inhibition of WEE1 enhanced the antitumor activity of PD-1 blockade by promoting cytotoxic NK (natural killer)-cell-mediated clearance (Hai et al., 2020). PDXs and organoid models can also be combined: such a living biobank was used to uncover new clinical combination treatment opportunities for uterine and colon cancer (Trendstalk, 2019). Other approaches like ex vivo manipulation of patient-derived cell cultures may complement these efforts to evaluate novel treatment combinations (Crystal et al., 2014).